Vivos Inc (RDGL)

[nathanial]

NEWS
Vivos Inc Provides Update on Initial Indication for Use for RadioGelTM Therapy
Richland WA, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), We are excited to announce that based on the recommendation of our Medical Advisory Board, Vivos Inc has decided on treating inaccessible (non-resectable) cancerous lymph nodes, particularly in the head, neck, and lungs as its initial Indication of Use.

We believe that Radiogel therapy represents a significant improvement over the current lymph node therapy options, which should make the FDA more supportive. Additionally, lymph node tumor therapy is confined to the nodes, which allows for positive therapeutic results to be apparent within two months, thereby allowing for a relatively short trial timeline.

Dr. Mike Korenko stated, “We have recently accelerated our effort to reach our goal of human therapy while continuing to expand our Isopet® animal therapy. We are being advised by three doctors from Mayo Clinic, since they have an excellent reputation for lymph node therapy. Our objective is to obtain approval to perform our clinical trials at Mayo. We have begun the pre-clinical testing which is necessary to obtain the FDA issuance of the Investigational Device Exemption (IDE). As we have discussed previously, our Board advised that RadioGel could be used to treat as many as 14 different cancer types and we continue to believe that treating basal cell and squamous cell skin cancer is an important indication. However, we now believe that non-resectable lymph node cancer is a better initial indication for use as we pursue FDA approval.”

About Vivos Inc. (OTCQB: RDGL)